Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Aug 19, 2019

Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD

Aug 01, 2019

Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference

Jul 17, 2019

Fulcrum Therapeutics Announces Pricing of Initial Public Offering

Apr 23, 2019

Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy

Feb 20, 2019

Fulcrum Therapeutics Appoints Christopher Moxham, Ph.D. as SVP, Discovery

Jan 04, 2019

Fulcrum Therapeutics to Present at Biotech Showcase 2019

Jan 03, 2019

Fulcrum Therapeutics Appoints Biotech Executive Bryan Stuart as Chief Operating Officer

Investor Tools

Privacy Policy
EU Privacy Policy
Terms of Use

Twitter
LinkedIn
Instagram

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact